Combined use of ibandronate and eldecalcitol in postmenopausal Japanese women with osteoporosis.

Purpose: To evaluate the effect of combined use of ibandronate and eldecalcitol for 6 to 12 months on bone mineral density (BMD) and bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis.

Methods: BMD and bone strength of the proximal femur were evaluated in 78 postmenopausal women (mean age, 73.6 years) who underwent treatment for osteoporosis with combined use of ibandronate and eldecalcitol for at least 6 months.

Comparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis.

Objective: This study analyzes whether concomitant raloxifene (RLX) or bisphosphonates (BP) plus eldecalcitol (ELD) has excessive suppressive effects on a bone resorption marker during the first 6 months of treatment in postmenopausal women in real-world setting.

Methods: 285 postmenopausal osteoporotic patients who had been treated with RLX or BP plus ELD were evaluated the bone resorption marker, serum tartrate resistant acid phosphatase-5b (TRACP-5b), during the first 6 months of treatment.

Results: In drug-naïve group (not received osteoporosis medications before the administration, n=70), the concomitant RLX or BP with ELD significantly decreased levels of TRACP-5b without severe suppression.

Correlation between a bone resorption marker and structural geometry of the proximal femur in osteoporotic women treated with raloxifene.

Purpose: To assess correlations between a bone resorption marker and the structural geometry of the proximal femur in raloxifene-treated postmenopausal women with osteoporosis.

Methods: 45 postmenopausal, osteoporotic women aged 57 to 79 (mean, 67) years underwent raloxifene treatment (60 mg/day) for 12 months. Serum type-I collagen crosslinked N-telopeptide (sNTX) as the bone resorption marker was measured at baseline and 6 months, whereas hip structure analysis (HSA) parameters of the femur (neck, intertrochanter, and shaft) were measured at baseline and 12 months using dual energy X-ray absorptiometry.

Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis.

The purpose of this study was to clarify the effects of a 1-year treatment with either alendronate or risedronate on the proximal femoral geometry among Japanese women with osteoporosis by hip structure analysis. Postmenopausal women who had taken at least 90% of their prescription for alendronate (35 mg/week, 94 patients) or risedronate (17.5 mg/week, 181 patients) for 1 year were retrospectively analyzed.

Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women with osteoporosis.

The purpose of this study was to clarify the effects of 2-year treatment with raloxifene on the proximal femoral geometry among Japanese patients with osteoporosis by hip structure analysis. One hundred ninety-eight community-dwelling postmenopausal women with osteoporosis were enrolled. The structural variables were areal bone mineral density (BMD), cross-sectional area (CSA), section modulus (index of resistance to bending forces), and buckling ratio (index of cortical instability).

[Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].

The effects of treatment with raloxifene on bone quality (proximal femur geometry) are evaluated by hip structure analysis. Raloxifene shows the significant improvement of the index of resistance to bending forces (section modulus) in Japanese patients with postmenopausal osteoporosis. Raloxifene decreased the endocortical bone resorption without affecting the periosteal bone formation.

[Evidence and utility of etidronate for the treatment of osteoporosis].

Etidronate is the first bisphosphonate for the treatment of osteoporosis in Japan. Etidronate is useful for the treatment of postmenopausal osteoporosis, glucocorticoid induced osteoporosis, osteoporosis in men, and disused osteoporosis. Etidronate is less effective than other bisphosphonate, such as alendronate and risedronate, in reduction of fracture risk especially non-vertebral fracture, although bone mineral density in femoral neck is significantly increased.